Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Batskikh S, Morozov S, Sokolova E. Immunological patterns and clinical forms of primary biliary cholangitis. World J Hepatol 2026; 18(11): 126007 [DOI: 10.4254/wjh.126007]
Sergey Batskikh, Elizaveta Sokolova, Department of Hepatology, Moscow Clinical Scientific Center N.A. A.S. Loginov, Moscow 111123, Russia
Sergey Morozov, Department of Gastroenterology, Hepatology and Nutrition, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow 115446, Russia
Sergey Morozov, Chair of Gastroenterology, Russian Medical Academy of Continuing Professional Education, Moscow 125993, Russia
Co-first authors: Sergey Batskikh and Sergey Morozov.
Author contributions: Batskikh S, Morozov S and Sokolova E conceived the idea for the manuscript, reviewed the literature; Batskikh S and Morozov S drafted the manuscript, both authors have made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-first authors of the paper.
AI contribution statement: During preparation of the initial version of this manuscript Claude (Claude Sonnet 5 by Anthropic) was used to assist with the following: Copy-editing and language polishing of the manuscript text, transforming the literature references from the field notes made by the authors in MS Word document and formatting the reference list into numbered Vancouver/WJG style with in-text citation numbering. All AI-assisted outputs were reviewed, verified, and edited by the authors, who take full responsibility for the accuracy, integrity, and originality of the manuscript's content. Hereby we confirm that no AI tool or service was used to design the study, collect or analyze data, or determine scientific conclusions of our manuscript. No AI tools and services were used for the revision of the manuscript. The AI tool is not listed as an author, consistent with ICMJE authorship criteria.
Supported by Research grant of Ministry of Science and Higher Education of Russia, No. FGMF-2025-0003; Research grant of Moscow Healthcare Department, 2026.
Conflict-of-interest statement: None of the authors has a conflict of interest in regard to this review
Corresponding author: Sergey Morozov, MD, PhD, Senior Researcher, Department of Gastroenterology, Hepatology and Nutrition, Federal Research Center of Nutrition, Biotechnology and Food Safety, Kashirskoye Shosse 21, Moscow 115446, Russia. morosoffsv@mail.ru
Received: July 22, 2026 Revised: September 1, 2026 Accepted: September 21, 2026 Published online: November 27, 2026 Processing time: 121 Days and 0.4 Hours
Abstract
Primary biliary cholangitis (PBC) is a chronic, slowly progressive autoimmune liver disease of unknown etiology, characterized by the presence of antimitochondrial antibodies (AMA) and/or PBC-specific antinuclear antibodies (ANA), nonsuppurative destructive cholangitis and, in most cases, cholestasis, which in its natural course leads to biliary cirrhosis. PBC is considered a rare disease predominantly affecting middle-aged women. However, a significant rise in the incidence and prevalence of PBC has been observed worldwide recently, especially among men and younger individuals. In addition to “classic” PBC (AMA-positive with cholestasis), there are several special variants of the disease: AMA-negative PBC (without AMA with the presence of other markers or completely seronegative), variant syndromes such as PBC with features of autoimmune hepatitis (AIH) or with features of primary sclerosing cholangitis (PSC), and AMA-positive PBC without cholestatic syndrome (most likely a preclinical stage of the disease). These forms have clinical and laboratory differences and distinct autoantibody profiles. Some variants may have a more severe course and worse clinical outcomes. Studying the prevalence and clarifying the clinical and laboratory features of these special forms of PBC is of substantial scientific and practical importance for assessing disease prognosis, development of new approaches to its diagnosis and treatment. Early recognition of these variants remains a challenge. For the well-characterized forms - in particular PBC-AIH variant syndrome - timely, form-appropriate therapy is associated with slower progression and better transplant-free survival. For the less well-defined categories, including AMA-positive individuals without cholestasis, completely seronegative PBC and the PBC-PSC variant, a comparable benefit is plausible but has not been demonstrated prospectively. This article is a narrative review supported by a structured search of PubMed, EMBASE and Google Scholar covering 2005-2025, from which 101 studies were included, with a further 28 sources identified by citation tracking and hand-searching; no formal risk-of-bias appraisal, evidence grading or meta-analysis was performed. The six-form classification and the diagnostic algorithm presented here are the authors’ hypothesis-generating proposal, not validated or guideline-endorsed entities, and require prospective external validation.
Core Tip: Primary biliary cholangitis (PBC) is increasingly recognized as a spectrum of distinct clinical-immunological forms rather than a single, uniform disease. This review proposes a practical classification of six forms of PBC - “classic” antimitochondrial antibodies (AMA)-positive with cholestasis, AMA-negative/seropositive, completely seronegative, PBC-autoimmune hepatitis (AIH) variant syndrome, AMA-positive PBC without cholestasis, and PBC-primary sclerosing cholangitis variant syndrome - based on autoantibody profile, biochemistry, and histology. A diagnostic algorithm is suggested to help clinicians better recognize these forms of PBC, provide individualized and timely treatment, and enhance surveillance. Of the six forms, three (classic AMA-positive PBC, AMA-negative PBC and PBC-AIH variant syndrome) correspond to entities recognized in international guidance; the remainder are conceptual categories proposed by the authors. The classification and algorithm are hypothesis-generating, are not guideline-endorsed, and require prospective validation before use in practice.